Yan Leyfman: First-in-Human CRISPR-Cas9 CISH Knockout in Tumor-Infiltrating Lymphocytes for Metastatic GI Cancers
Yan Leyfman, Co-founder and executive director of MedNews Week, shared a post on LinkedIn:
“Researchers evaluated a first-in-human approach using CRISPR-Cas9 to knock out CISH, an intracellular immune checkpoint, in tumor-infiltrating lymphocytes (TILs) for patients with metastatic GI cancers.
- Safe administration confirmed
- Early signs of anti-tumor activity
- 1 patient with MSI-high colorectal cancer had a complete, ongoing response >21 months
This study highlights a novel strategy to overcome resistance to current immunotherapies.”
Title: Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial.
Authors: Emil Lou, Modassir S Choudhry, Prof Timothy K Starr, Timothy D Folsom, Jason Bell, Blaine Rathmann, Anthony P DeFeo, Jihyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Akshat Sarkari, Prof R Scott McIvor, Thomas A Murray, Prof Jeffrey S Miller,Madhuri Rao, Prof Eric Jensen, Branden S Moriarity.
You can reade the Full Article on The Lancet Oncology.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023